公开(公告)号：US20190134197A1

公开(公告)日：2019-05-09

申请号：US16304509

申请日：2017-05-25

Applicant: GRIFFITH UNIVERSITY

Inventor： Surendran Mahalingam ,  Adam Taylor

IPC: A61K39/42 ,  A61P31/14 ,  A61K39/12

Abstract: The invention relates to a vaccine comprising live attenuated recombinant alphavirus comprising mutated capsid protein. The invention also relates to a method of preventing a subject from contracting an alphaviral infection that would otherwise produce clinical signs of disease. In an embodiment the mutated capsid protein is Chikungunya virus (CHIKV) capsid protein having a mutated nucleolar localisation signal/sequence (NoLS), preferably the mutant NLS 101/95.

公开(公告)号：US20210401983A1

公开(公告)日：2021-12-30

申请号：US17372803

申请日：2021-07-12

Applicant: GRIFFITH UNIVERSITY

Inventor： Surendran Mahalingam ,  Adam Taylor

IPC: A61K39/42 ,  A61K39/12 ,  C12N7/00 ,  C07K19/00 ,  C07K14/005 ,  G01N33/569 ,  A61P31/14

Abstract: The invention relates to a vaccine comprising live attenuated recombinant alphavirus comprising mutated capsid protein. The invention also relates to a method of preventing a subject from contracting an alphaviral infection that would otherwise produce clinical signs of disease. In an embodiment the mutated capsid protein is Chikungunya virus (CHIKV) capsid protein having a mutated nucleolar localisation signal/sequence (NoLS), preferably the mutant NLS 101/95.

公开(公告)号：US11090384B2

公开(公告)日：2021-08-17

申请号：US16304509

申请日：2017-05-25

Applicant: GRIFFITH UNIVERSITY

Inventor： Surendran Mahalingam ,  Adam Taylor

IPC: A61K39/12 ,  A61P31/14 ,  C07K14/005 ,  C07K19/00 ,  C07K7/00 ,  G01N33/569 ,  A61K39/42 ,  C12N7/00 ,  A61K39/00

Abstract: The invention relates to a vaccine comprising live attenuated recombinant alphavirus comprising mutated capsid protein. The invention also relates to a method of preventing a subject from contracting an alphaviral infection that would otherwise produce clinical signs of disease. In an embodiment the mutated capsid protein is Chikungunya virus (CHIKV) capsid protein having a mutated nucleolar localisation signal/sequence (NoLS), preferably the mutant NLS 101/95.